Drug Profile
VDA 1214
Alternative Names: VDA1214Latest Information Update: 28 Jun 2020
Price :
$50
*
At a glance
- Originator VidacPharma
- Class Small molecules
- Mechanism of Action Keratinocyte modulators; Voltage-dependent anion channel modulators; Voltage-gated potassium channel modulators; Voltage-gated sodium channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jun 2020 No recent reports of development identified for research development in Solid-tumours in Israel
- 26 May 2016 Early research in Solid tumours in Israel (unspecified route) before May 2016 (VidacPharma pipeline; May 2016)